Rocky Mountain Cancer Center

Aurora, Colorado 80012

3 studies enrolling now · 13 studies all time

What they study most

AML, B Cells--Tumors, B-Cell Malignancies, B-cell Lymphoma, Breast Cancer, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Diffuse Large B-cell Lymphoma Refractory, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Follicular B-cell Non-Hodgkin's Lymphoma

Studies at this site

• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
• Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy — Completed
• Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers — Completed
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer — Completed
• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies — Completed
• A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes — Stopped early
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias — Stopped early
• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma — Stopped early